Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria

Dennis W. Bartholomew, Mark L. Batshaw, Robert H. Allen, Charles R. Roe, David Rosenblatt, David Valle, Clair Ann Francomano

Research output: Contribution to journalArticle

Abstract

The use of hydroxocobalamin (OH-B12), betaine, carnitine, and folinic acid were studied in two children with the cobalamin C form of methylmalonic acidemia and homocystinuria. When daily injections of 1 mg OH-B12 were discontinued for 3 weeks, there was no significant change in total plasma homocysteine or methionine levels and only a modest increase in methylmalonate. Orally administered OH-B12 1 mg/d in one patient was associated with an increase in plasma homocystine and a decrease in methionine within 1 month. Withdrawal of betaine 250 mg/kg/d was also associated with a rise in plasma homocystine and a fall in methionine levels. Carnitine 100 mg/kg/d led to an increase in urinary excretion of propionylcarnitine, but did not affect plasma methylmalonate levels. No beneficial biochemical effect of follinic acid could be documented at a dose of 25 mg/d. Our results suggest that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using l-carnitine and folinic acid, we could not document their effectiveness in these two patients.

Original languageEnglish (US)
Pages (from-to)32-39
Number of pages8
JournalJournal of Pediatrics
Volume112
Issue number1
DOIs
StatePublished - 1988

Fingerprint

Betaine
Carnitine
Homocystine
Methionine
propionylcarnitine
Leucovorin
Therapeutics
Hydroxocobalamin
Injections
Homocysteine
hydroxide ion
Methylmalonic acidemia with homocystinuria
Acids

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria. / Bartholomew, Dennis W.; Batshaw, Mark L.; Allen, Robert H.; Roe, Charles R.; Rosenblatt, David; Valle, David; Francomano, Clair Ann.

In: Journal of Pediatrics, Vol. 112, No. 1, 1988, p. 32-39.

Research output: Contribution to journalArticle

Bartholomew, Dennis W. ; Batshaw, Mark L. ; Allen, Robert H. ; Roe, Charles R. ; Rosenblatt, David ; Valle, David ; Francomano, Clair Ann. / Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria. In: Journal of Pediatrics. 1988 ; Vol. 112, No. 1. pp. 32-39.
@article{53b849b2110a4235b5d73ded9c010df4,
title = "Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria",
abstract = "The use of hydroxocobalamin (OH-B12), betaine, carnitine, and folinic acid were studied in two children with the cobalamin C form of methylmalonic acidemia and homocystinuria. When daily injections of 1 mg OH-B12 were discontinued for 3 weeks, there was no significant change in total plasma homocysteine or methionine levels and only a modest increase in methylmalonate. Orally administered OH-B12 1 mg/d in one patient was associated with an increase in plasma homocystine and a decrease in methionine within 1 month. Withdrawal of betaine 250 mg/kg/d was also associated with a rise in plasma homocystine and a fall in methionine levels. Carnitine 100 mg/kg/d led to an increase in urinary excretion of propionylcarnitine, but did not affect plasma methylmalonate levels. No beneficial biochemical effect of follinic acid could be documented at a dose of 25 mg/d. Our results suggest that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using l-carnitine and folinic acid, we could not document their effectiveness in these two patients.",
author = "Bartholomew, {Dennis W.} and Batshaw, {Mark L.} and Allen, {Robert H.} and Roe, {Charles R.} and David Rosenblatt and David Valle and Francomano, {Clair Ann}",
year = "1988",
doi = "10.1016/S0022-3476(88)80114-8",
language = "English (US)",
volume = "112",
pages = "32--39",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria

AU - Bartholomew, Dennis W.

AU - Batshaw, Mark L.

AU - Allen, Robert H.

AU - Roe, Charles R.

AU - Rosenblatt, David

AU - Valle, David

AU - Francomano, Clair Ann

PY - 1988

Y1 - 1988

N2 - The use of hydroxocobalamin (OH-B12), betaine, carnitine, and folinic acid were studied in two children with the cobalamin C form of methylmalonic acidemia and homocystinuria. When daily injections of 1 mg OH-B12 were discontinued for 3 weeks, there was no significant change in total plasma homocysteine or methionine levels and only a modest increase in methylmalonate. Orally administered OH-B12 1 mg/d in one patient was associated with an increase in plasma homocystine and a decrease in methionine within 1 month. Withdrawal of betaine 250 mg/kg/d was also associated with a rise in plasma homocystine and a fall in methionine levels. Carnitine 100 mg/kg/d led to an increase in urinary excretion of propionylcarnitine, but did not affect plasma methylmalonate levels. No beneficial biochemical effect of follinic acid could be documented at a dose of 25 mg/d. Our results suggest that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using l-carnitine and folinic acid, we could not document their effectiveness in these two patients.

AB - The use of hydroxocobalamin (OH-B12), betaine, carnitine, and folinic acid were studied in two children with the cobalamin C form of methylmalonic acidemia and homocystinuria. When daily injections of 1 mg OH-B12 were discontinued for 3 weeks, there was no significant change in total plasma homocysteine or methionine levels and only a modest increase in methylmalonate. Orally administered OH-B12 1 mg/d in one patient was associated with an increase in plasma homocystine and a decrease in methionine within 1 month. Withdrawal of betaine 250 mg/kg/d was also associated with a rise in plasma homocystine and a fall in methionine levels. Carnitine 100 mg/kg/d led to an increase in urinary excretion of propionylcarnitine, but did not affect plasma methylmalonate levels. No beneficial biochemical effect of follinic acid could be documented at a dose of 25 mg/d. Our results suggest that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using l-carnitine and folinic acid, we could not document their effectiveness in these two patients.

UR - http://www.scopus.com/inward/record.url?scp=0023830785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023830785&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(88)80114-8

DO - 10.1016/S0022-3476(88)80114-8

M3 - Article

C2 - 3257264

AN - SCOPUS:0023830785

VL - 112

SP - 32

EP - 39

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -